SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Lotfi L)
 

Search: WFRF:(Lotfi L) > (2015-2019) > Increased proportio...

  • Ilander, MUniversity of Helsinki, Finland; Helsinki University Hospital, Finland (author)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2016-11-28
  • Springer Science and Business Media LLC,2017
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-310824
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-310824URI
  • https://doi.org/10.1038/leu.2016.360DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-128517URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135731104URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-137599URI
  • https://lup.lub.lu.se/record/b50be235-800d-40c2-a45e-e6f74fdec7b0URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Nordic Cancer Union; Finnish Society of Hematology; Biomedicum Helsinki Foundation; Research Foundation of Blood Diseases in Finland; Academy of Finland; Finnish Cancer Organizations; Signe and Ane Gyllenberg Foundation; Finnish Cancer Institute; Doctoral Programme in Clinical Research in the University of Helsinki
  • Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib-treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse-free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naïve CD56(bright) NK cells had decreased relapse-free survival. In addition, the TNF-α/IFN-γ cytokine secretion by NK cells correlated with the successful drug discontinuation. Our results highlight the role of NK cells in sustaining remission and strengthen the status of CML as an immunogenic tumor warranting novel clinical trials with immunomodulating agents.Leukemia advance online publication, 16 December 2016; doi:10.1038/leu.2016.360.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Olsson-Strömberg, UllaUppsala University,Uppsala universitet,Hematologi,Uppsala University Hospital, Sweden; Uppsala University, Sweden(Swepub:uu)ulols170 (author)
  • Schlums, HKarolinska Institutet,Karolinska Institute, Sweden,Karolinska University Hospital (author)
  • Guilhot, JCHU Poitiers, France,Poitiers University Hospital (author)
  • Brück, OUniversity of Helsinki, Finland; Helsinki University Hospital, Finland (author)
  • Lähteenmäki, HUniversity of Helsinki, Finland; Helsinki University Hospital, Finland (author)
  • Kasanen, TUniversity of Helsinki, Finland; Helsinki University Hospital, Finland (author)
  • Koskenvesa, PUniversity of Helsinki, Finland; Helsinki University Hospital, Finland (author)
  • Söderlund, StinaUppsala University,Karolinska Institutet,Uppsala universitet,Hematologi,Uppsala University Hospital, Sweden; Uppsala University, Sweden; Karolinska University Hospital, Sweden,Finnish Red Cross Blood Serv, Finland,Heidelberg University, Germany,University of Helsinki, Finland; Helsinki University Hospital, Finland; University of Helsinki, Finland,Finnish Red Cross Blood Transfusion Service(Swepub:uu)stiso746 (author)
  • Höglund, MartinUppsala universitet,Hematologi,Uppsala University Hospital, Sweden(Swepub:lu)kgen-mho (author)
  • Markevärn, BUmeå University Hospital, Sweden,Norrland University Hospital,Örebro University Hospital (author)
  • Själander, AndersUmeå universitet,Medicin,Sundsvall Research Unit, Umeå University,Umeå University, Sweden(Swepub:umu)anssjr90 (author)
  • Lotfi, Kourosh,1966-Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US,Linköping University Hospital(Swepub:liu)koulo97 (author)
  • Dreimane, ArtaLinköpings universitet,Institutionen för klinisk och experimentell medicin,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US,Linköping University Hospital(Swepub:liu)artdr13 (author)
  • Lübking, A.Skåne University Hospital, Sweden(Swepub:lu)stem-alb (author)
  • Holm, E.Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-hen (author)
  • Björeman, M (author)
  • Lehmann, SörenUppsala universitet,Hematologi,Karolinska Univ Hosp, Div Hematol, Dept Med, Stockholm, Sweden(Swepub:uu)sorle534 (author)
  • Stenke, LKarolinska Institutet,Karolinska University Hospital, Sweden (author)
  • Ohm, LKarolinska University Hospital, Sweden (author)
  • Gedde-Dahl, TOslo University Hospital, Norway,Norwegian Radium Hospital (author)
  • Majeed, WStavanger University Hospital, Norway (author)
  • Ehrencrona, H (author)
  • Koskela, S (author)
  • Saussele, S (author)
  • Mahon, F-XUniversity of Bordeaux Segalen, France (author)
  • Porkka, K (author)
  • Hjorth-Hansen, HSt Olavs University Hospital, Norway (author)
  • Bryceson, Y TKarolinska Institutet,Karolinska Institute, Sweden,Karolinska University Hospital (author)
  • Richter, J.Lund University,Lunds universitet,Avdelningen för molekylärmedicin och genterapi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Molecular Medicine and Gene Therapy,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-jri (author)
  • Mustjoki, S (author)
  • University of Helsinki, Finland; Helsinki University Hospital, FinlandHematologi (creator_code:org_t)

Related titles

  • In:Leukemia: Springer Science and Business Media LLC31:5, s. 1108-11160887-69241476-5551

Internet link

Find in a library

  • Leukemia (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view